BACKGROUND: Hemolytic uremic syndrome (HUS) can be triggered by Shiga toxin producing Escherichia coli (STEC) infection or it can be defined as atypical HUS (aHUS) if it is related to uncontrolled complement activation. aHUS is characterized by a high incidence of recurrence after kidney transplantation, and it can also occur de novo in transplant recipients. Eculizumab is used both to prevent and to treat aHUS following kidney transplantation. In this paper, we report our centre experience and we present 4 cases of HUS in patients who underwent kidney transplantation. METHODS: This is a single-center experience about HUS development in transplanted patients. RESULTS: Patient 1 with end-stage renal disease (ESRD) due to STEC-HUS undergoing kidney transplantation without prophylactic therapy with eculizumab. Patient 2 with HUS secondary to an episode of diarrhea at 8 years old. After a slow progression to ESRD, she underwent kidney transplantation and she received prophylactic therapy with eculizumab due to the presence of anti-complement factor H antibodies. Patient 3 underwent pre-emptive living donor ABO-incompatible kidney transplantation and developed HUS secondary to antibody-mediated rejection. Patient 4 developed de novo HUS 16 years after kidney transplantation without a known cause. CONCLUSION: The correct diagnosis of HUS and the identification of the complement component alterations in case of aHUS are important parameters required to predict the risk of post-transplant recurrence of the disease. In the cases we reported, eculizumab has been found to be effective both to prevent and to treat aHUS following kidney transplantation.
BACKGROUND:Hemolytic uremic syndrome (HUS) can be triggered by Shiga toxin producing Escherichia coli (STEC) infection or it can be defined as atypical HUS (aHUS) if it is related to uncontrolled complement activation. aHUS is characterized by a high incidence of recurrence after kidney transplantation, and it can also occur de novo in transplant recipients. Eculizumab is used both to prevent and to treat aHUS following kidney transplantation. In this paper, we report our centre experience and we present 4 cases of HUS in patients who underwent kidney transplantation. METHODS: This is a single-center experience about HUS development in transplanted patients. RESULTS:Patient 1 with end-stage renal disease (ESRD) due to STEC-HUS undergoing kidney transplantation without prophylactic therapy with eculizumab. Patient 2 with HUS secondary to an episode of diarrhea at 8 years old. After a slow progression to ESRD, she underwent kidney transplantation and she received prophylactic therapy with eculizumab due to the presence of anti-complement factor H antibodies. Patient 3 underwent pre-emptive living donor ABO-incompatible kidney transplantation and developed HUS secondary to antibody-mediated rejection. Patient 4 developed de novo HUS 16 years after kidney transplantation without a known cause. CONCLUSION: The correct diagnosis of HUS and the identification of the complement component alterations in case of aHUS are important parameters required to predict the risk of post-transplant recurrence of the disease. In the cases we reported, eculizumab has been found to be effective both to prevent and to treat aHUS following kidney transplantation.
Authors: Maria L Gonzalez Suarez; Charat Thongprayoon; Michael A Mao; Napat Leeaphorn; Tarun Bathini; Wisit Cheungpasitporn Journal: J Clin Med Date: 2019-06-27 Impact factor: 4.241
Authors: José Portoles; Ana Huerta; Emilia Arjona; Eva Gavela; Marisa Agüera; Carlos Jiménez; Teresa Cavero; Domingo Marrero; Santiago Rodríguez de Córdoba; Fritz Diekmann Journal: Clin Kidney J Date: 2020-08-13
Authors: John Fredy Nieto-Rios; Monica Zuluaga-Quintero; Julio Cesar Valencia-Maturana; Diana Carolina Bello-Marquez; Arbey Aristizabal-Alzate; Gustavo Adolfo Zuluaga-Valencia; Lina Maria Serna-Higuita; Luis Fernando Arias Journal: J Bras Nefrol Date: 2021 Oct-Dec